RBC Capital Markets increased its price target for Biohaven Ltd. from $19 to $22, while maintaining a 'Sector Perform' rating. This adjustment follows the FDA's acceptance of Biohaven's resubmitted application for Vyglxia, an experimental treatment, signaling an improved regulatory outlook for the drug.
RBC Capital Markets raised its price target on Biohaven Ltd. from $19 to $22, while keeping a 'Sector Perform' rating. This positive adjustment stems directly from the FDA's acceptance of Biohaven's resubmitted application for Vyglxia, a drug targeting spinocerebellar ataxia. The FDA's decision to review the application and schedule an advisory committee meeting significantly de-risks the regulatory pathway for Vyglxia, which is a key pipeline asset for Biohaven. This news is a short-term positive for Biohaven, as it indicates progress towards potential market approval and could attract increased investor interest. The long-term implication depends on the eventual FDA decision, but the current development reduces uncertainty and offers an opportunity for traders betting on successful drug approval.